Oncolytic poliovirus for human tumors
AssigneeDuke University
InventorsMatthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
Life of this patent
Estimating the term…
Abstract
Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
Claims25
A method of treating a human harboring a solid tumor which expresses NECL5 (nectin-like protein 5), said method comprising the steps of:
- administering directly to the solid tumor in the human a PVS-RIPO chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5′ untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame, whereby the tumor is treated.
A method of treating a human harboring a solid tumor which expresses NECL5 (nectin-like protein 5), said method comprising the steps of:
- testing a solid tumor to ascertain that it expresses NECL5;
- and
- administering directly to the tumor in the human a PVS-RIPO chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5′ untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame, wherein the administering is stereotactically guided, intracerebral infusion with convection enhanced delivery.
Dependencies are inferred from the claim text.